Journal of Equine Veterinary Science
Volume 28, Issue 4 , Pages 209-214 , April 2008

A Review of the Efficacy of Tiludronate in the Horse

  • Lacy Kamm, DVM
    • ,
  • Wayne McIlwraith, BVSc, DACVS, PhD
    • ,
  • Chris Kawcak, DVM, PhD, DACVS

      Affiliations

    • Corresponding Author InformationReprint requests: Chris Kawcak, DVM, PhD, DACVS, Gail Holmes Equine Orthopaedic Research Center, Colorado State University, 300 W. Drake Rd., Fort Collins, CO 80523.

References 

  1. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998;19:80–100
  2. Woo T, Adachi J. Role of bisphosphonates and calcitonin in the prevention and treatment of osteoporosis. Best Pract Res Clin Rheumatol. 2001;15:469–481
  3. Drudge-Coates L. Skeletal complications and the use of bisphosphonates in metastatic prostate cancer. Int J Palliative Nursing. 2006;12:462–468
  4. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Min Res. 1998;13:581–589
  5. Yoshida M, Tokuda H, Ishisaki A, Kanno Y, Shimizu K, Kozawa O. Tiludronate inhibits prostaglandin F2α- induced vascular endothelial growth factor synthesis in osteoblasts. Mol Cell Endocrinol. 2005;239:59–66
  6. Russell RGG, Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, et al. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Min Res. 1999;14:53–65
  7. David P, Nguyen H, Barbier A, Baron R. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H+-ATPase. J Bone Min Res. 1996;11:1498–1507
  8. Murakami H, Takahashi N, Tanaka S, Nakamura I, Udagawa N, Nakajo S, et al. Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts. Bone. 1997;20:399–04
  9. Monkkonen J, Simila J, Rogers MJ. Effects of tiludronate and ibandronate on the secretion of proinflammatory cytokines and nitric oxide from macrophages in vitro. Life Sci. 1998;62:PL95–PL102
  10. Nakaya H, Osawa G, Iwasaki N, Cochran DL, Kamoi K, Oates TW. Effects of bisphosphonates on matrix metalloproteinase enzymes in human periodontal ligament cells. J Periodontol. 2000;71:1158–1166
  11. Drake W, Kendler D, Brown J. Consensus statement on the modern therapy of Paget's disease of bone from a Western Osteoporosis Alliance Symposium. Clin Ther. 2001;23:620–626
  12. Michou L, Collet C, Laplanche JL, Orcel P, Cornelis F. Genetics of Paget's disease of bone. Joint Bone Spine. 2006;73:243–248
  13. Reginster JY, Lecart MP, Deroisy R, Sarlet N, Denis D, Ethgen D, et al. Prevention of postmenopausal bone loss by tiludronate. Lancet. 1989;2:1469–1471
  14. Reginster JY, Christianson C, Roux C, Fechtenbaum J, Rouillon A, Tou KP. Intermittent cyclic tiludronate in the treatment of osteoporosis. Osteoporos Int. 2001;12:169–177
  15. Chestnut CH. Tiludronate: development as an osteoporosis therapy. Bone. 1995;17:517S–519S
  16. Fraser WD, Stamp TC, Creek RA, Sawyer JP, Picot C. A double-blind, multicentre, placebo-controlled study of tiludronate in Paget's disease of bone. Postgrad Med J. 1997;73:496–502
  17. Roux C, Gennari C, Farrerons J, Devogelaer JP, Mulder H, Kruse HP, et al. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis Rheum. 1995;38:851–858
  18. Committee for medicinal products: Tiludronic acid, disodium salt summary report. The European Agency for Evaluating Medicinal Products. January 2001. Available at: http://www.emea.eu.int/pdfs/vet/mrls/077401en.pdf. Accessed March 2006.
  19. Thibaud D, Guyonnet J, Toutain PL. Pharmacological approaches of dose determination with tiludronate for use in the horse. J Vet Pharmacol Ther. 2003;26:200–201
  20. Varela A, Lepage OM, Doucet M, Marcoux M, Garnero P. Tiludronate in horses: tolerance and short-term effects on bone metabolism. J Bone Miner Res. 2001;16:S407
  21. Lepage O. Personal communication, 2005.
  22. Denoix J-M, Thibaud D, Riccio B. Tiludronate as a new therapeutic agent in the treatment of navicular disease: a double-blind placebo-controlled clinical trial. Equine Vet J. 2003;35:407–413
  23. Blunden A, Dyson S, Murray R, Schramme M. Histopathology in horses with chronic palmar foot pain and age-matched controls. Part 1: Navicular bone and related structures. Equine Vet J. 2006;38:15–22
  24. Dyson SJ, Murray R, Schramme MC. Lameness associated with foot pain: results of magnetic resonance imaging in 199 horses (January 2001–December 2003) and response to treatment. Equine Vet J. 2005;37:113–121
  25. Riccio B, Thibaud D, Denoix J-M. A double-blind placebo-controlled trial of tiludronate in the treatment of bone spavin. BEVA Congress. 2002;
  26. Bourrelier S. Spavin. Tildren. 2003. Available at: http://www.tildren.com/TildrenVetUK.nsf. Accessed March 2006.
  27. Dyson SJ. Are there any advances in the treatment of distal hock joint pain? Proceedings International Symposium on Diseases of the Icelandic Horse; 2004.
  28. Schulze T. Fallbericht: Seltene diagnose und erfolgreiche therapie. Pferde Spiegel. 2005;March:140–145
  29. Coudry V, Thibaud D, Riccio B, Audigie F, Didierlaurent D, Denoix J-M. Efficacy of tiludronate in the treatment of horses with signs of pain associated with osteoarthritic lesions of the thoracolumbar vertebral column. Am J Vet Res. 2007;48:329–337
  30. Gray AW, Davies ME, Jeffcott LB. Generation and activity of equine osteoclasts in vitro: effects of the bisphosphonate pamidronate. Res Vet Sci. 2002;72:105–113
  31. Bilezikian JP. Osteonecrosis of the jaw: do bisphosphonates pose a risk?. N Engl J Med. 2006;355:2278–2281
  32. McGuigan MP, Cauvin E, Schramme MC, Pardoe CH, May SA, Wilson AM. A double-blind placebo-controlled trial of bisphosphonate in the control of navicular syndrome. Proceedings British Equine Veterinary Association Congress. 2000;203

 Refereed

PII: S0737-0806(08)00068-3

doi: 10.1016/j.jevs.2008.02.007

Journal of Equine Veterinary Science
Volume 28, Issue 4 , Pages 209-214 , April 2008

Article Tools